Chair, Mark J. Levis, MD, PhD, discusses acute myeloid leukemia in this CME/MOC/AAPA activity titled “Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors.” For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DDE865. CME/MOC/AAPA credit will be available until August 1, 2024.

свернуть